CNR1 and Obesity: In the first experiment, hyperlipidemic E3L.CETP mice were fed with or without supplementation of the CB1R inverse agonist rimonabant for 4 weeks to investigate the short-term effects on dyslipidemia, energy expenditure, and adipose tissue thermogenesis in an obesity-independent context.